Maryan Ali

Extracorporeal photopheresis as GVHD prophylaxis: No impact on gut microbiota—a randomized controlled trial

Per Ole Iversen, Kristian Holm, Corinna Bang, Geir E. Tjønnfjord et autres

no, de (code pays fourni par la source)

Addressing Knowledge Gaps in the Early Detection of Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation: An Official American Thoracic Society Research Statement

Guang‐Shing Cheng, Ajay Sheshadri, Kirsten M. Williams, Joe L. Hsu et autres

Abstract Background Bronchiolitis obliterans syndrome (BOS) is a late-onset noninfectious pulmonary complication of allogeneic hematopoietic cell transplant (HCT) that is often diagnosed at an advanced stage with severe lung impairment. Increasing use of HCT for the treatment of hematologic diseases worldwide translates …

us, ca, ch, fr, hk, de (code pays fourni par la source)

Epigenetic aging of human blood cells is influenced by the age of the host body

Petter Holland, Mette Istre, Maryan Ali, Tobias Gedde‐Dahl et autres

Allogenic hematopoietic stem cell transplantation is a therapeutic procedure performed over a wide range of donor and recipient age combinations, representing natural experiments of how the age of the recipient affects aging in transplanted donor cells in vivo. We measured DNA methylation …

no, us, de (code pays fourni par la source)

Extracorporeal Photopheresis as Graft-versus-Host Disease Prophylaxis: A Randomized Controlled Trial

Maryan Ali, Tobias Gedde‐Dahl, Liv Osnes, Flavie Perrier et autres

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the sole curative option for many patients diagnosed with hematologic malignancies. A major obstacle is graft-versus-host disease (GVHD), causing significant morbidity and mortality. Extracorporeal photopheresis (ECP) is an increasingly applied treatment for GVHD, owing in …

no (code pays fourni par la source)

Role of Extracorporeal Photopheresis in Prevention of Graft-Versus-Host Disease in Patients Treated with Allogeneic Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial

Maryan Ali, Tobias Gedde‐Dahl, Marit B. Veierød, Geir E. Tjønnfjord et autres

Abstract Introduction In many patients diagnosed with a hematological malignancy, the disease cannot be totally eradicated by conventional therapeutic approaches, and for them allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative option. A major complication of allo-HSCT is graft-versus-host disease …

no (code pays fourni par la source)

Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival

Maryan Ali, B. Grønvold, Mats Remberger, Ingerid Weum Abrahamsen et autres

Anti-thymocyte globulin (ATG) is commonly used to prevent graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). To evaluate the impact of ATG as part of the GvHD prophylaxis in our institution, we report the outcome of 415 patients with matched …

no, se, gb (code pays fourni par la source)

Superior Graft-versus-Host Disease-Free Relapse-Free Survival in Matched Unrelated Donor Hematopoietic Stem Cell Transplantation with Anti-Thymocyte Globulin (ATG) Compared to Matched Related Donor without ATG

Mats Remberger, Geir E. Tjønnfjord, Ingerid Weum Abrahamsen, Maryan Ali et autres

The use of anti-T cell globulin (ATG) in allogeneic stem cell transplantation with matched unrelated donors (MUDs) is considered standard of care in many transplant centers, as these patients are at higher risk of developing acute and chronic graft-versus-host disease (GVHD). Several …

no, se (code pays fourni par la source)

HLA-DPB1 mismatch reduce relapse and improve survival in T-cell replete unrelated donor allogeneic stem cell transplantation

B. Grønvold, Maryan Ali, Mats Remberger, Jonas Mattsson et autres

no, se, ca (code pays fourni par la source)

The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Sibling Donors Receiving Peripheral Blood Stem-Cells

Yngvar Fløisand, Jonas Mattsson, Maryan Ali, B. Grønvold et autres

Background The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) is influenced by many factors (underlying disease, HLA-matching, patient and donor age, CMV serostatus, co-morbidities, conditioning regimen, GVHD prophylaxis and graft source and composition). The number of T-cells contained in the graft …

ca, no, se (code pays fourni par la source)

The Effect of Donor Age on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation

Mats Remberger, Maryan Ali, Bjørn Christer Grønvold, Geir E. Tjønnfjord et autres

Background The age of patients admitted to HSCT is increasing. The median age of adult patients is close to 60 years at many centers. With a sibling donor this means that in most cases an older donor will be used. There are …

se, no, ca (code pays fourni par la source)

The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors

Mats Remberger, B. Grønvold, Maryan Ali, Jonas Mattsson et autres

/kg) correlated with less acute GVHD (aGVHD) II-IV. We conclude that the CD34 cell dose has an impact on the outcome of HSCT from sibling donor PBSCs.

no, se, ca (code pays fourni par la source)

The Impact of HLA-DPB1 Mismatch in T-Cell Replete Unrelated Donor Allogeneic Stem Cell Transplantation

B. Grønvold, Maryan Ali, Mats Remberger, Jonas Mattsson et autres

High-resolution matching of donor-recipient HLA improves outcome in allogeneic stem cell transplants. Matching for HLA-A, -B, -C, –DRB1 and –DQ is mandatory in our transplant centre, to identify 10/10 or 9/10 matched unrelated donors. High resolution matching for DPB1 has been added …

no (code pays fourni par la source)